Bone marrow derived stromal cells from myelodysplastic syndromes are altered but not clonally mutated in vivo

骨髓增生异常综合征患者的骨髓间充质干细胞发生改变,但未发生体内克隆性突变。

阅读:7
作者:Johann-Christoph Jann ,Maximilian Mossner ,Vladimir Riabov ,Eva Altrock ,Nanni Schmitt ,Johanna Flach ,Qingyu Xu ,Verena Nowak ,Julia Obländer ,Iris Palme ,Nadine Weimer ,Alexander Streuer ,Ahmed Jawhar ,Ali Darwich ,Mohammad Jawhar ,Georgia Metzgeroth ,Florian Nolte ,Wolf-Karsten Hofmann ,Daniel Nowak

Abstract

The bone marrow (BM) stroma in myeloid neoplasms is altered and it is hypothesized that this cell compartment may also harbor clonal somatically acquired mutations. By exome sequencing of in vitro expanded mesenchymal stromal cells (MSCs) from n = 98 patients with myelodysplastic syndrome (MDS) and n = 28 healthy controls we show that these cells accumulate recurrent mutations in genes such as ZFX (n = 8/98), RANK (n = 5/98), and others. MDS derived MSCs display higher mutational burdens, increased replicative stress, senescence, inflammatory gene expression, and distinct mutational signatures as compared to healthy MSCs. However, validation experiments in serial culture passages, chronological BM aspirations and backtracking of high confidence mutations by re-sequencing primary sorted MDS MSCs indicate that the discovered mutations are secondary to in vitro expansion but not present in primary BM. Thus, we here report that there is no evidence for clonal mutations in the BM stroma of MDS patients.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。